List of Biocytogen patents

Patents where

Current Assignee

Name

Biocytogen

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11272695 Genetically modified non-human animal with human or chimeric PD-1	Patent 11272695 was granted and assigned to Biocytogen on March, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11272695	March 15, 2022
‌ US Patent 11317611 Genetically modified non-human animal with human or chimeric PD-L1		Biocytogen	Biocytogen	United States Patent and Trademark Office	11317611	May 3, 2022
‌ US Patent 10314297 DNA knock-in system	Patent 10314297 was granted and assigned to Biocytogen on June, 2019 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10314297	June 11, 2019
‌ US Patent 11439132 Humanized transgenic animal		Biocytogen	Biocytogen	United States Patent and Trademark Office	11439132	September 13, 2022
‌ US Patent 11505806 Genetically modified non-human animal with human or chimeric OX40		Biocytogen	Biocytogen	United States Patent and Trademark Office	11505806	November 22, 2022
‌ US Patent 11534502 Genetically modified non-human animal with human or chimeric TIGIT	Patent 11534502 was granted and assigned to Biocytogen on December, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11534502	December 27, 2022
‌ US Patent 11352429 Anti-PD-1 antibodies and uses thereof	Patent 11352429 was granted and assigned to Biocytogen on June, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11352429	June 7, 2022
‌ US Patent 10925264 Genetically modified non-human animal with human or chimeric LAG-3	Patent 10925264 was granted and assigned to Biocytogen on February, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10925264	February 23, 2021
‌ US Patent 11350614 Genetically modified non-human animal with human or chimeric CD28		Biocytogen	Biocytogen	United States Patent and Trademark Office	11350614	June 7, 2022
‌ US Patent 11279948 Genetically modified non-human animal with human or chimeric OX40		Biocytogen	Biocytogen	United States Patent and Trademark Office	11279948	March 22, 2022
‌ US Patent 10912287 Genetically modified mice expressing humanized PD-1	Patent 10912287 was granted and assigned to Biocytogen on February, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10912287	February 9, 2021
‌ US Patent 11564381 Genetically modified non-human animal with human or chimeric LAG3			Biocytogen	United States Patent and Trademark Office	11564381	January 31, 2023
‌ US Patent 11464876 Genetically modified mouse comprising a chimeric TIGIT	Patent 11464876 was granted and assigned to Biocytogen on October, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11464876	October 11, 2022
‌ US Patent 11071290 Genetically modified non-human animal with human or chimeric CTLA-4	Patent 11071290 was granted and assigned to Biocytogen on July, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11071290	July 27, 2021
‌ US Patent 11497198 Genetically modified mice expressing humanized CD40	Patent 11497198 was granted and assigned to Biocytogen on November, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11497198	November 15, 2022
‌ US Patent 11154040 Genetically modified non-human animal with human or chimeric CD137	Patent 11154040 was granted and assigned to Biocytogen on October, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11154040	October 26, 2021
‌ US Patent 10973212 Genetically modified non-human animal with human or chimeric SIRPa	Patent 10973212 was granted and assigned to Biocytogen on April, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10973212	April 13, 2021
‌ US Patent 10945418 Genetically modified non-human animal with human or chimeric PD-L1	Patent 10945418 was granted and assigned to Biocytogen on March, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10945418	March 16, 2021
‌ US Patent 11096383 Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene	Patent 11096383 was granted and assigned to Biocytogen on August, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11096383	August 24, 2021
‌ US Patent 11234420 Method for constructing PD-1 gene modified humanized animal model and use thereof	Patent 11234420 was granted and assigned to Biocytogen on February, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11234420	February 1, 2022
‌ US Patent 10980222 Genetically modified non-human animal with human or chimeric CD27	Patent 10980222 was granted and assigned to Biocytogen on April, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10980222	April 20, 2021
‌ US Patent 11240995 Genetically modified non-human animal with human or chimeric TIM-3	Patent 11240995 was granted and assigned to Biocytogen on February, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11240995	February 8, 2022
‌ US Patent 11071289 DNA knock-in system	Patent 11071289 was granted and assigned to Biocytogen on July, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11071289	July 27, 2021
‌ US Patent 10945419 Genetically modified non-human animal with human or chimeric GITR	Patent 10945419 was granted and assigned to Biocytogen on March, 2021 by the United States Patent and Trademark Office.		Biocytogen	United States Patent and Trademark Office	10945419	March 16, 2021

24 results

0 selected

24 results

0 selected